PET/CT and PET/MR in Soft Tissue Sarcoma: An Update

Area of Science:

• Pediatric Oncology
• Surgical Oncology
• Radiation Oncology

Background:

• Soft tissue sarcomas represent 6%-8% of pediatric cancers, with rhabdomyosarcoma being the most common subtype.
• Rhabdomyosarcomas are aggressive, high-grade tumors with metastatic potential, necessitating comprehensive treatment strategies.
• Nonrhabdomyosarcoma soft tissue sarcomas encompass a range of grades, often managed with surgery, but frequently requiring combined modality treatments.

Purpose of the Study:

• To outline staging, risk stratification, and imaging guidelines for pediatric soft tissue sarcomas.
• To align with Children's Oncology Group (COG) clinical trial protocols.
• To integrate recommendations from the International Soft Tissue Sarcoma Database Consortium and European trials.

Main Methods:

• Review of staging and risk stratification protocols used in COG trials.
• Analysis of imaging recommendations for diagnosis and monitoring.
• Synthesis of data from international consortia and European studies.

Main Results:

• COG guidelines provide a framework for risk-adapted, multimodal therapy including surgery, radiotherapy, and chemotherapy.
• Specific imaging protocols are crucial for accurate staging and treatment planning.
• International data complements COG guidelines, offering a broader perspective on management.

Conclusions:

• Standardized staging and risk stratification are essential for effective pediatric soft tissue sarcoma treatment.
• Multimodal approaches, guided by clinical trials and international data, improve outcomes.
• Adherence to COG trial guidelines ensures consistent and evidence-based care for pediatric patients.